FrancophonIA/ELRC3.0 huggingface dataset:
English: Exploratory subgroup analyses were performed in patients with PD-L1 expression ≥ 1%, exploring prior (neo)adjuvant treatment, BRCA1/2 mutation and asymptomatic brain metastases at baseline.
Croatian: Eksploracijske analize podskupina provedene su u bolesnika s ekspresijom PD-L1 ≥ 1%, a istraživali su se prethodno (neo)adjuvantno liječenje, prisutnost mutacije BRCA1/2 i asimptomatske moždane metastaze na početku ispitivanja.
English: • inflammation of the heart muscle
Croatian: • upala srčanog mišića
English: e Includes reports of white blood cell count decreased and leukopenia.
Croatian: e Uključuje prijavljene slučajeve smanjenog broja bijelih krvnih stanica i leukopenije.
English: Myocarditis occurred in < 0.1% (2/8,000) of patients across all atezolizumab clinical trials in multiple tumour types and treatment combinations.
Croatian: Miokarditis se javio u < 0,1% (2/8000) bolesnika u svim kliničkim ispitivanjima atezolizumaba primijenjenog kod različitih vrsta tumora i u različitim terapijskim kombinacijama.
English: OS interim analysis*
Croatian: Interim analiza podataka za OS*
English: The educational programme is aimed at increasing awareness and providing information concerning the signs and symptoms of certain important identified risks of atezolizumab, including immunerelated pneumonitis, hepatitis, colitis, hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, neuropathies, meningoencephalitis, pancreatitis, and infusion related reactions, and how to manage them.
Croatian: Edukacijski program namijenjen je povećanju razine svijesti i pružanju informacija o znakovima i simptomima nekih važnih utvrđenih rizika kod primjene atezolizumaba, uključujući imunološki uzrokovan pneumonitis, hepatitis, kolitis, hipotireozu, hipertireozu, insuficijenciju nadbubrežne žlijezde, hipofizitis, šećernu bolest tipa 1, neuropatije, meningoencefalitis, pankreatitis i reakcije na infuziju, te o tome kako liječiti te nuspojave.
English: Treatment with atezolizumab must be permanently discontinued for Grade 3 or Grade 4 events (ALT or AST > 5.0 x ULN or blood bilirubin > 3 x ULN).
Croatian: Liječenje atezolizumabom mora se trajno prekinuti u slučaju događaja 3. ili 4. stupnja (ALT ili AST > 5,0 x GGN ili bilirubin u krvi > 3 x GGN).
English: Seventy-five percent of patients received only one prior platinum-based therapeutic regimen.
Croatian: Sedamdeset i pet posto (75%) bolesnika prethodno je primilo samo jedan protokol temeljen na platini.
English: The patient will be provided with the patient alert card and instructed to carry the card at all times.
Croatian: Bolesnik će dobiti karticu s upozorenjima za bolesnika, uz naputak da karticu uvijek mora nositi sa sobom.
English: Mutagenicity studies have not been performed to establish the mutagenic potential of atezolizumab.
Croatian: Nisu provedena ispitivanja kojima bi se utvrdio mutageni potencijal atezolizumaba.
English: Each mL contains 60 mg of atezolizumab.
Croatian: Jedan ml sadrži 60 mg atezolizumaba.
English: OS results were similar for patients aged < 65 and ≥ 65 subgroups, respectively.
Croatian: Rezultati za OS bili su slični u podskupini bolesnika u dobi od < 65 godina i podskupini bolesnika u dobi od ≥ 65 godina.
English: No. of events (%)
Croatian: Broj događaja (%)
English: Patients with EGFR mutations or ALK rearrangements should have been previously treated with tyrosine kinase inhibitors.
Croatian: Bolesnici s EGFR mutacijama ili izmjenama u redoslijedu baza u genu ALK prethodno su morali biti liječeni inhibitorima tirozin kinaze.
English: A population pharmacokinetic analysis suggests that steady-state is obtained after 6 to 9 weeks (2 to 3 cycles) of repeated dosing.
Croatian: Populacijska farmakokinetička analiza ukazuje na to da se stanje dinamičke ravnoteže postiže nakon 6 - 9 tjedana (2 - 3 ciklusa) ponovljenog doziranja.
English: Other clinically significant adverse events which were observed more frequently in the atezolizumab, bevacizumab, paclitaxel, and carboplatin arm were epistaxis, haemoptysis, cerebrovascular accident, including fatal events.
Croatian: Drugi klinički značajni štetni događaji opaženi češće u skupini koja je primala atezolizumab, bevacizumab, paklitaksel i karboplatin bili su epistaksa, hemoptiza i cerebrovaskularni incident, uključujući smrtne slučajeve.
English: What Tecentriq contains
Croatian: Što Tecentriq sadrži
English: Carcinogenicity studies have not been performed to establish the carcinogenic potential of atezolizumab.
Croatian: Nisu provedena ispitivanja kojima bi se utvrdio kancerogeni potencijal atezolizumaba.
English: • low oxygen levels, which may cause shortness of breath as a consequence of inflamed lungs
Croatian: • niske razine kisika, koje mogu uzrokovati nedostatak zraka, a posljedica su upale pluća
English: Grade 3 or 4 hyperglycaemia (fasting glucose > 250 mg/dL or 13.9 mmol/L)
Croatian: Hiperglikemija 3. ili 4. stupnja (glukoza natašte > 250 mg/dl ili 13,9 mmol/l)
English: vomiting, bleeding or bruising, dark urine, and stomach pain
Croatian: krvarenje ili nastanak modrica, tamnu mokraću i bol u trbuhu
English: Sverige Roche AB
Croatian: Roche AB
English: Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.
Croatian: Vezivanje PD-L1 za receptore PD-1 i B7.1 na T-stanicama i antigen-prezentirajućim stanicama potiskuje aktivnost citotoksičnih T-stanica, proliferaciju T-stanica i proizvodnju citokina.
English: 79639 Grenzach-Whylen
Croatian: 79639 Grenzach-Whylen NJEMAČKA
English: Cohort 1 included 45 patients (38%) with ECOG performance status of 0, 50 patients (42%) with ECOG performance status of 1 and 24 patients (20%) with ECOG performance status of 2, 35 patients (29%) with no Bajorin risk factors (ECOG performance status ≥ 2 and visceral metastasis), 66 patients (56%) with one Bajorin risk factor and 18 patients (15 %) with two Bajorin risk factors, 84 patients (71%) with impaired renal function (glomerular filtration rate [GFR] < 60 mL/min), and 25 patients (21%) with liver metastasis.
Croatian: Kohorta 1 uključivala je 45 bolesnika (38%) s funkcionalnim ECOG statusom 0, 50 bolesnika (42%) s funkcionalnim ECOG statusom 1 i 24 bolesnika (20%) s funkcionalnim ECOG statusom 2, 35 bolesnika (29%) bez Bajorinovih faktora rizika (funkcionalni ECOG status ≥ 2 i visceralne metastaze), 66 bolesnika (56%) s jednim Bajorinovim faktorom rizika i 18 bolesnika (15 %) s dva Bajorinova faktora rizika, 84 bolesnika (71%) s oštećenjem bubrežne funkcije (brzina glomerularne filtracije [engl. glomerular filtration rate, GFR] < 60 ml/min) i 25 bolesnika (21%) s jetrenim metastazama.
English: Nervous system disorders Very Common peripheral neuropathyl , dizziness, headache
Croatian: Poremećaji živčanog sustava Vrlo često periferna neuropatijal, omaglica, glavobolja
English: • low number of red blood cells, which can cause tiredness and shortness of breath
Croatian: • nizak broj crvenih krvnih stanica, koji može uzrokovati umor i nedostatak zraka
English: Atezolizumab in combination therapy
Croatian: Atezolizumab u kombiniranoj terapiji
English: At the time of the final analysis for PFS, patients had a median follow up time of 15.3 months.
Croatian: U trenutku provedbe završne analize podataka za PFS, medijan praćenja bolesnika iznosio je 15,3 mjeseca.
English: Patients should be monitored for symptoms of motor and sensory neuropathy.
Croatian: Bolesnike treba nadzirati zbog mogućih simptoma motoričke i senzorne neuropatije.
English: Patients were randomised to receive atezolizumab 840 mg or placebo by intravenous infusions on days 1 and 15 of every 28-day cycle, plus nab-paclitaxel (100 mg/m2) administered via intravenous infusion on days 1, 8 and 15 of every 28-day cycle.
Croatian: Bolesnici su bili randomizirani za primanje atezolizumaba u dozi od 840 mg ili placeba intravenskom infuzijom 1. i 15. dana svakog 28-dnevnog ciklusa plus nab-paklitaksela (100 mg/m2) primijenjenog intravenskom infuzijom 1., 8. i 15. dana svakog 28-dnevnog ciklusa.
English: Patient demographics and baseline tumour disease in patients with PD-L1 expression ≥1% were generally representative of the broader study population.
Croatian: Demografske značajke bolesnika i tumorska bolest na početku ispitivanja u bolesnika s ekspresijom PD-L1 ≥ 1% načelno su dobro predstavljali širu ispitivanu populaciju.
English: Details for the significant adverse reactions for atezolizumab when given in combination are presented if clinically relevant differences were noted in comparison to atezolizumab monotherapy.
Croatian: Podaci za značajne nuspojave kod primjene atezolizumaba u kombiniranoj terapiji navedeni su ako su primijećene klinički značajne razlike u odnosu na monoterapiju atezolizumabom.
English: Grade 3 or 4: (ALT or AST > 5 x ULN
Croatian: 3. ili 4. stupnja: (ALT ili AST > 5 x GGN
English: Tecentriq used in combination with anticancer medicines The following side effects have been reported in clinical trials when Tecentriq is given in combination with anticancer medicines:
Croatian: Tecentriq u kombinaciji s drugim lijekovima za liječenje raka Sljedeće nuspojave prijavljene su u kliničkim ispitivanjima u kojima se Tecentriq primjenjivao u kombinaciji s drugim lijekovima za rak:
English: Includes report of nephritis, Henoch-Schonlein Purpura nephritis.
Croatian: Uključuje prijavljen slučaj nefritisa, nefritisa izazvanog Henoch-Schönleinovom purpurom.
English: No clinical data are available on the possible effects of atezolizumab on fertility.
Croatian: Nisu dostupni klinički podaci o mogućim učincima atezolizumaba na plodnost.
English: Exposure to atezolizumab increased dose proportionally over the dose range 1 mg/kg to 20 mg/kg including the fixed dose 1,200 mg administered every 3 weeks.
Croatian: Izloženost atezolizumabu povećavala se proporcionalno dozi u rasponu doza od 1 mg/kg do 20 mg/kg, uključujući fiksnu dozu od 1200 mg svaka 3 tjedna.
English: The majority of patients were white (72.1%), 53.9% of patients within the chemotherapy arm received vinflunine, 71.4% of patients had at least one poor prognostic risk factor and 28.8% had liver metastases at baseline.
Croatian: Većina bolesnika bila je bijele rase (72,1%), 53,9% bolesnika u skupini liječenoj kemoterapijom primalo je vinflunin, 71,4% bolesnika imalo je najmanje jedan faktor rizika za lošu prognozu, a njih 28,8% imalo je jetrene metastaze na početku ispitivanja.
English: Tecentriq has not been studied in patients with moderate or severe hepatic impairment (see section 5.2).
Croatian: Tecentriq se nije ispitivao u bolesnika s umjerenim ili teškim oštećenjem jetrene funkcije (vidjeti dio 5.2).
English: PFS, ORR and DOR results of IMpassion130 for patients with PD-L1 expression ≥ 1% at the time of the final analysis for PFS with a median survival follow up of 13 months are summarized in Table 6 with Kaplan-Meier curves for PFS in Figure 4.
Croatian: Rezultati za PFS, ORR i trajanje odgovora u ispitivanju IMpassion130 među bolesnicima s ekspresijom PD-L1 ≥ 1%, u trenutku završne analize PFS-a i nakon medijana praćenja preživljenja od 13 mjeseci, sažeto su prikazani u Tablici 6, a Kaplan-Meierove krivulje PFS-a na Slici 4.
English: • The other ingredients are L-histidine, glacial acetic acid, sucrose, polysorbate 20 and water for injections.
Croatian: • Drugi sastojci su L-histidin, ledena acetatna kiselina, saharoza, polisorbat 20 i voda za injekcije.
English: Common hypokalaemia, hyponatraemia, hyperglycaemia hypokalaemia, hyponatraemia, hypomagnesaemia
Croatian: Često hipokalijemija, hiponatrijemija, hiperglikemija hipokalijemija, hiponatrijemija, hipomagnezijemija
English: • have any history of inflammation of your lungs (called pneumonitis)
Croatian: • ako ste ikada imali upalu pluća (koja se zove pneumonitis)
English: • followed by adequate storage of the prepared solution for intravenous infusion to ensure maintenance of the aseptic conditions.
Croatian: • Pripremljenu otopinu za intravensku infuziju treba čuvati na odgovarajući način kako bi se održali aseptični uvjeti.
English: Dose reductions of Tecentriq are not recommended.
Croatian: Ne preporučuje se smanjivati dozu lijeka Tecentriq.
English: At the time of the interim OS analysis, patients had a median follow-up of 19.7 months.
Croatian: U trenutku provedbe interim analize podataka za OS, medijan praćenja bolesnika iznosio je 19,7 mjeseci.
English: • low levels of magnesium, which can cause weakness and muscle cramping, numbness and pain in the arms and legs
Croatian: • niske razine magnezija, koje mogu uzrokovati slabost i mišićne grčeve te utrnulost i bol u rukama i nogama
English: Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to immune-related rejection of the developing foetus resulting in foetal death.
Croatian: Ispitivanja na životinjama pokazala su da inhibicija puta PD-L1/PD-1 može dovesti do imunološki uzrokovanog odbacivanja ploda u razvoju i tako dovesti do smrti ploda.
English: Myasthenic syndrome
Croatian: Mijastenički sindrom
English: Bladder was the primary tumour site for 71.1% of patients and 25.4% of patients had upper tract urothelial carcinoma.
Croatian: Mokraćni mjehur bio je primarno sijelo tumora u 71,1% bolesnika, dok je njih 25,4% imalo karcinom urotela gornjih mokraćnih putova.
English: In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.
Croatian: U slučaju predoziranja potrebno je pažljivo nadzirati bolesnike zbog moguće pojave znakova ili simptoma nuspojava te uvesti odgovarajuće simptomatsko liječenje.
English: Chemical and physical in-use stability has been demonstrated for up to 24 hours at ≤ 30 °C and for up to 30 days at 2°C to 8°C from the time of preparation.
Croatian: Dokazana je kemijska i fizikalna stabilnost tijekom najviše 24 sata na temperaturi ≤ 30°C ili tijekom najviše 30 dana na temperaturi od 2°C do 8°C od trenutka pripreme.
English: The majority of patients were male (65%), white (80%), and 9% had brain metastases and most patients were current or previous smokers (97%).
Croatian: Većina je bolesnika bila muškog spola (65%) i bijele rase (80%), 9% bolesnika imalo je moždane metastaze, a većina bolesnika bili su aktivni ili bivši pušači (97%).
English: These results should be interpreted with caution due to the open-label design of the study.
Croatian: Zbog otvorenog dizajna ispitivanja, te rezultate treba tumačiti uz oprez.
English: Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2
Croatian: Funkcionalni ECOG status ≥ 2
English: At the time of the primary analysis, patients had a median survival follow up time of 13.9 months.
Croatian: U trenutku provođenja primarne analize medijan praćenja preživljenja iznosio je 13,9 mjeseci.
English: • severe reactions associated with infusion (events occurring during the infusion or within one day of the infusion): may include fever, chills, shortness of breath and flushing.
Croatian: • teške reakcije na infuziju (događaje koji nastupaju tijekom infuzije ili unutar jednog dana nakon nje): mogu uključivati vrućicu, zimicu, nedostatak zraka i navale crvenila
English: Weekly administration of atezolizumab to female monkeys at an estimated AUC approximately 6 times the AUC in patients receiving the recommended dose caused an irregular menstrual cycle pattern and a lack of newly formed corpora lutea in the ovaries which were reversible.
Croatian: Primjena atezolizumaba jedanput na tjedan ženkama majmuna, u dozi kojom je postignut procijenjeni AUC približno 6 puta veći od onoga koji se postiže u bolesnika liječenih preporučenom dozom, uzrokovala je neredovite menstruacijske cikluse i izostanak nastanka novih žutih tijela u jajnicima, ali ti su učinci bili reverzibilni.
English: • inflammation of the mouth or lips
Croatian: • upala usne šupljine ili usana
English: 79639 Grenzach-Wyhlen
Croatian: 79639 Grenzach-Wyhlen Njemačka
English: l Includes reports of neuropathy peripheral, autoimmune neuropathy, peripheral sensory neuropathy, polyneuropathy, herpes zoster, peripheral motor neuropathy, neuralgic amyotrophy, peripheral sensorimotor neuropathy, toxic neuropathy, axonal neuropathy, lumbosacral plexopathy, neuropathic arthropathy, peripheral nerve infection.
Croatian: Uključuje prijavljene slučajeve periferne neuropatije, autoimune neuropatije, periferne senzorne neuropatije, polineuropatije, herpesa zostera, periferne motoričke neuropatije, neuralgične amiotrofije, periferne senzomotoričke neuropatije, toksične neuropatije, aksonske neuropatije, poremećaja lumbosakralnog pleksusa, neuropatske artropatije, infekcije perifernih živaca.
English: Table 12: Summary of efficacy (IMpower133) Key efficacy endpoints
Croatian: Tablica 12: Sažetak rezultata za djelotvornost (IMpower133) Ključne mjere ishoda za djelotvornost
English: • Reminder to carry the Patient Alert Card at all times and to show it to all healthcare professionals that may treat them.
Croatian: • Podsjetnik za bolesnike da uvijek sa sobom moraju nositi Karticu s upozorenjima za bolesnika i da je moraju pokazati svim zdravstvenim radnicima koji će ih možda liječiti.
English: Use of atezolizumab in urothelial carcinoma for previously untreated patients who are considered cisplatin ineligible
Croatian: Primjena atezolizumaba za liječenje urotelnog karcinoma u prethodno neliječenih bolesnika koji se ne smatraju pogodnima za liječenje cisplatinom
English: The data below reflect information for significant adverse reactions for atezolizumab as monotherapy in clinical studies (see section 5.1).
Croatian: Podaci u nastavku odražavaju podatke o značajnim nuspojavama kod monoterapije atezolizumabom u kliničkim ispitivanjima (vidjeti dio 5.1).
English: Based on an independent Data Monitoring Committee (iDMC) recommendation following an early review of survival data, accrual of patients on the atezolizumab monotherapy treatment arm whose tumours have a low PD-L1 expression (less than 5% of immune cells staining positive for PD-L1 by immunohistochemistry) was stopped after observing decreased overall survival for this subgroup.
Croatian: Na temelju preporuke neovisnog povjerenstva za praćenje podataka nakon rane ocjene podataka o preživljenju, uključivanje bolesnika čiji su tumori pokazivali nisku razinu ekspresije PD-L1 (manje od 5% imunosnih stanica s pozitivnom PD-L1 ekspresijom pri imunohistokemijskom bojanju) u skupinu koja je primala monoterapiju atezolizumabom prekinuto je nakon što je opaženo smanjenje ukupnog preživljenja u toj podskupini.
English: OS comparisons between treatment arms in patients with PD-L1 expression ≥1% were not formally tested, as per the pre-specified analysis hierarchy.
Croatian: Usporedbe OS-a između liječenih skupina u bolesnika s ekspresijom PD-L1 ≥ 1% nisu se formalno testirale prema unaprijed specificiranoj hijerarhijskoj analizi.
English: A total of 287 patients were randomised 1:1 to receive either atezolizumab (1,200 mg by intravenous infusion every 3 weeks until loss of clinical benefit) or docetaxel (75 mg/m2 by intravenous infusion on day 1 of each 3-week cycle until disease progression).
Croatian: Ukupno je 287 bolesnika bilo randomizirano u omjeru 1:1 za primanje atezolizumaba (1200 mg intravenskom infuzijom svaka 3 tjedna do gubitka kliničke koristi) ili docetaksela (75 mg/m2 intravenskom infuzijom 1. dana svakog 3-tjednog ciklusa do progresije bolesti).
English: Blood and lymphatic system disorders Very common anaemia, thrombocytopeniac, neutropeniad, leukopeniae
Croatian: Poremećaji krvi i limfnog sustava Vrlo često anemija, trombocitopenijac, neutropenijad, leukopenijae
English: • type 1 diabetes, including acid in the blood produced from diabetes (diabetic ketoacidosis): symptoms may include feeling more hungry or thirsty than usual, need to urinate more often, weight loss, and feeling tired
Croatian: • šećernu bolest tipa 1, uključujući kiselinu u krvi koja nastaje zbog šećerne bolesti (dijabetička ketoacidoza): simptomi mogu uključivati pojačan osjećaj gladi ili žeđi, češću potrebu za mokrenjem, gubitak tjelesne težine i umor
English: It is not known if Tecentriq gets into breast milk.
Croatian: Nije poznato izlučuje li se Tecentriq u majčino mlijeko.
English: Neutropenia and peripheral neuropathies occurring during treatment with atezolizumab and nabpaclitaxel may be reversible with interruptions of atezolizumab and/or nab-paclitaxel.
Croatian: Neutropenija i periferne neuropatije koje se jave tijekom liječenja atezolizumabom i nab-paklitakselom mogu se povući nakon privremenog prekida primjene atezolizumaba i/ili nab-paklitaksela.
English: Patients were treated until loss of clinical benefit as assessed by the investigator or unacceptable toxicity.
Croatian: Bolesnici su se liječili do gubitka kliničke koristi prema ocjeni ispitivača ili pojave neprihvatljive toksičnosti.
English: m Includes reports of Guillain-Barré syndrome and demyelinating polyneuropathy.
Croatian: Uključuje prijavljene slučajeve Guillain-Barréova sindroma i demijelinizirajuće polineuropatije.
English: The primary efficacy endpoint was OS.
Croatian: Primarna mjera ishoda za djelotvornost bio je OS.
English: • blood tests showing low levels of potassium (hypokalaemia) or sodium (hyponatremia)
Croatian: • nalazi krvnih pretraga koji ukazuju na niske razine kalija (hipokalijemija) ili natrija
English: Most patients were male (81%), and the majority of patients were White (91%).
Croatian: Većina bolesnika bili su muškarci (81%) i većina je bolesnika bila bijele rase (91%).
English: In addition, nab-paclitaxel is administered on days 8 and 15.
Croatian: Nab-paklitaksel se uz to primjenjuje i 8. i 15. dana.
English: • 1,680 milligrams (mg) every four weeks.
Croatian: • 1680 miligrama (mg) svaka četiri tjedna
English: Across multiple phase III studies, 13.1 % to 36.4% of patients developed treatment-emergent anti-drug antibodies (ADAs).
Croatian: Prema podacima iz više ispitivanja faze III, u 13,1% do 36,4% bolesnika su se tijekom liječenja razvila protutijela na lijek.
English: 472 patients described atezolizumab pharmacokinetics for the dose range: 1 to 20 mg/kg with a linear two-compartment disposition model with first-order elimination.
Croatian: Populacijska analiza koja je obuhvatila 472 bolesnika opisala je farmakokinetiku atezolizumaba u rasponu doza od 1 do 20 mg/kg linearnim modelom dispozicije s dva odjeljka i eliminacijom prvog reda.
English: Hyperthyroidism:
Croatian: Hipertireoza:
English: Stratifiedǂ hazard ratio (95% CI) 12-month OS (%)**
Croatian: Stratificiranǂ omjer hazarda (95% CI) 12-mjesečni OS (%)*
English: • a cancer that affects the lungs, called small cell lung cancer (SCLC).
Croatian: • rak koji zahvaća pluća, a zove se “rak pluća malih stanica“ (engl. small cell lung cancer, SCLC).
English: There is no information on overdose with atezolizumab.
Croatian: Nema podataka o predoziranju atezolizumabom.
English: Nausea, diarrhoea, stomatitis, fatigue, pyrexia, mucosal inflammation, decreased appetite, weight decreased, hypertension and proteinuria were reported higher (≥5% difference) in patients receiving atezolizumab in combination with bevacizumab,
Croatian: Mučnina, proljev, stomatitis, umor, pireksija, upala sluznice, smanjen tek, smanjena tjelesna težina, hipertenzija i proteinurija prijavljeni su s većom učestalošću (razlika ≥ 5%) u bolesnika koji su primali atezolizumab u kombinaciji s bevacizumabom, paklitakselom i karboplatinom.
English: Patients with the following conditions were excluded from clinical trials: a history of autoimmune disease, history of pneumonitis, active brain metastasis, HIV, hepatitis B or hepatitis C infection, significant cardiovascular disease and patients with inadequate hematologic and end-organ function.
Croatian: U klinička ispitivanja nisu bili uključeni bolesnici koji su imali sljedeća stanja: autoimunu bolest u anamnezi, pneumonitis u anamnezi, aktivne moždane metastaze, HIV infekciju, hepatitis B ili hepatitis C infekciju, značajnu kardiovaskularnu bolest ili nedostatnu hematološku funkciju i funkciju ciljnih organa (engl. end-organ).